In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts

Oncology Research

Volumn 11, Issue 3, 1999, Pages 153-159

  Song, Kaimei ^a   Cowan, Kenneth H ^a   Sinha, Birandra K ^a  

^a NONE   (United States)

Author keywords

Adenovirus; Cis piatinum; Combination gene therapy; Drug resistance; Gene therapy; Ovarian carcinoma; P53 gene

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; PROTEIN P53;

ADENOVIRUS; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; DRUG RESISTANCE; FEMALE; GENE THERAPY; GENETICS; HUMAN; METHODOLOGY; MORTALITY; MOUSE; NUDE MOUSE; OVARY TUMOR; SURVIVAL RATE; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE THERAPY; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032617993     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Takahashi, N.; Nau, M. M.; Chiba, I.; Brirer, M. J.; Rosenbcrg, R. K.; Vinacour, M.; Levutt, M.; Pass, H.; Gazader, A. F.; Minna, J. D. p53: A frequent target for genetic abnormalities in lung cancer. Science 246:491-494; 1989.
2. Clarke, A. R.; Purdie, C. A.; Harrison, D. J.; Morris, R. G.; Bird, C. C.; Hooper, M. L.; Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852; 1993.
3. Dulic', V.; Kaufmann, W. K.; Wilson, S. J.; Tlstry, T. D.; Lees, E., Harper, J. W.; Elledge, S. J.; Reed, S. I. p53-Dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced Gl arrest. Cell 76:1013-1023; 1994.
4. Michalovitz, D.; Halevy, O.; Oren, M. Conditional inhibition of transformation and cell proliferation by a temperature-sensitive mutant of p53. Cell 62:671-680; 1990.
5. Lowe, S. W.; Schmitt, E. M.; Smith, S. W.; Osborne, B. A.; Jacks, T. p53 Dependent apoptosis modulates the cytotoxicity of anticancer agents. Nature 362:847-849; 1993.
6. Lowe, S. W.; Bodis, S.; McClantry, A.; Remington, L.; Ruley, H. E.; Fisher, D. E.; Housman, D. E.; Jacks, T. p53 Status and the efficacy of cancer therapy in vivo. Science 266:807-810; 1994.
7. Rouby, S. E.; Thomas, A.; Costin, D.; Rosenberg, C. R.; Potescmil, M.; Silver, R.; Newcomb, E. W. p53 Gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82: 3452-3459; 1993.
8. Hsiao, M. H.; Yu, A. L.; Yeargin, J.; Ku, D.; Haas, M. Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase. Blood 83:2922-2927; 1994.
9. Myers, C. E.; Cowan, K. H.; Sinha, B. K.; Chabner, B. The phenomenon of pleiotropic drug resistance. In: DeVita, V. T.; Hellman, S.; Rosenberg, S. A., eds. Important advances in oncology. Amsterdam: Elsevier; 1987:27-38.
10. Gottesman, M. M.; Pastan, I. Resistance to multiple chemothcrapeutic agents in human cancer cells. Trends Pharmacol. Sci. 9: 54-58; 1988.
11. Reed, E.; Kohn, K. W. Platinum analogues. In: Chabner, B.; Collins, J. M., eds. Cancer chemotherapy: Principles & practices. Philadelphia: J. B. Lippincott Co.; 1990:465-490.
12. Ozols, R. F.; Young, R. C. Chemotherapy of ovarian cancer. Semin. Oncol. 11:251-263; 1991.
13. Andrew, P. A.; Velury, S.; Mann, S. C; Howell, S. B. cis-Diammine-dichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res. 48:67-73; 1988.
14. Parker, R. J.; Eastman, A.; Bostic-Burton, F.; Reed, E. Acquired cisplatinum resistance in human ovarian cancer cells is associated with enhanced repair of cisplatinum-DNA lesions and reduced drug accumulation. J. Clin. Invest. 87:772-777; 1991.
15. Fujiwara, T.; Grimm, E. A.; Mukhopadhyay, T.; Zhang, W. W.; Owen Schaub, L. B.; Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54:2287-2291; 1994.
16. Song, K.; Li, Z.; Seth, P.; Cowan, K. H.; Sinha, B. K. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinoma. Oncol. Res. 9:603-609; 1997.
17. Katayose, D.; Wersto, R. Cowan, K. H.; Seth, P. Effects of a recombinant adenovirus expressing WAF/Cipl on cell growth, cell cycle, and apoptosis. Cell Growth Differ. 6:1207-1212; 1995.
18. Li, Z.; Rakar, A.; Katayose, Y.; Kim, M.; Shanmugam, N.; Srivastva, S.; Moul, J. W.; McLeod, D. G.; Cowan, K. II; Seth, P. Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model. Gene Ther. 5:605-613; 1998.
19. Wang, Z.; Benchekroun, M. N.; Sinha, B. K. Sensitization of carboplatin and camptothecins by interleukin-1 against human ovarian carcinoma in vivo. Anticancer Res. 14:1723-1726; 1994.
20. Postethwaite, R. Liver damage induced in mice by human adenovirus type 5. Scottish Med. J. 18:131; 1973.
21. Duncan, S. J.; Gordon, F. C. A.; Gregory, D. W.; Mcphie, J. L.; Postlethwaite, R.; White, R.; Willcox, H. N. A. Infection of mouse liver by human adenovirus type 5. J. Gen. Virol. 40:45-61; 1978.
22. Chin, K. V.; Paslan, I.; Gottesman, M. M. Function and regulation of human multidrug resistance gene. Adv. Cancer Res. 60:157-180; 1993.
23. Dank, M. K.; Yalowich, J. C.; Beck, W. T. Atypical multiple drug resistance in a human leukemia cell line selected for resistance to teniposide (VM-26). Cancer Res. 47:1297-1301; 1987.
24. Sinha, B. K.; Mimnaugh, E. G. Free radicals and anticancer drug resistance: Oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. Free Radie. Biol. Med. 8:567-581; 1990.
25. Nigro, J. M.; Baker, J. S.; Preisinger, A. C.; Jessup, J. M.; Hosteller, R.; Cleary, K.; Bigner, S. II.; Davidson, N.; Bayline, S.; Device, P.; Glover, T.; Collins, F. C.; Weston, A.; Modali, R.; Harris, C. C.; Vogelslein, B. Mulation in p53 gene occur in diverse human tumor types. Nature 342:705-708; 1989.
26. Gallagher, W. M.; Cairney, M.; Scholl, B.; Roninson, I. B.; Brown, R. Idenlificalion of p53 genetic suppressor elemenls which confers resistance to cisplatin. Oncogene 14:185-193; 1997.
27. Perego, P.; Giarola, M.; Rigneti, S. C.; Supino, R.; Caserini, C; Delia, D.; Pierotti, M. A.; Miyashita, T.; Reed, J. C; Zunino, F. Association between cisplatin resistance and mutation of p53 gene and reduced Bax expression in ovarian carcinoma cell systems. Cancer Res. 56:556-562; 1996.
28. Nielsen, L. L.; Maneval, D. P53 Tumor supressor gene therapy for cancer. Cancer Gene Ther. 5:52-63; 1998.
29. Nielsen, L. L.; Gurnani, M.; Syed, J.; Dell, J.; Hartmen, B.; Cartwright, M.; Johnson, R. C. Recombinant El-deleted adenovirusmediated gene therapy for cancer: Efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenografl model. Hum. Gene Ther. 9:681-694; 1998.
30. Arah, I. N.; Song, K.; Seth, P.; Cowan, K. H.; Sinha, B. K. Role of wild type p53 in the enhancement of camptothecin cytotoxicity against human prostate cells. Anticancer Res. 18:1845-1850; 1998.